IMPAACT Studies in Development
The study you are looking for is in protocol development.
As the study protocol reaches Version 1.0, a study page will be developed.
|
Study Number (DAIDS ID) |
Study Title | Status |
|---|---|---|
|
IMPAACT 2021 (38530) |
Randomized Phase IB Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/delta 1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age |
In Development |
|
IMPAACT 2019 (38504) |
Phase I/II study of the pharmacokinetics, safety, and tolerability of dolutegravir/lamivudine/abacavir (Triumeq®) in HIV-1-infected children less than 12 years of age |
In Development |
|
IMPAACT 2020 (38505) |
Shortened Oral Treatment for Multidrug-Resistant Tuberculosis in Infants, Children and Adolescents (SMaRT Kids): A Phase III Randomized Multi-center Trial |
In Development |
|
IMPAACT 2016 (38506) |
Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence in Adolescents Living with HIV in Low Resource Settings |
In Development |
|
IMPAACT 2003B (12041) |
(Phoenix) Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant TB Patients |
In Development |